Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s treatment, new data show.

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic deafness.

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by Regeneron have seen notable improvements in hearing, according to new data from the CHORD trial.

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a mutation to the otoferlin gene. The company snapped up DB-OTO through its $109 million acquisition of Decibel Therapeutics in 2023.

Regeneron (NASDAQ:REGN) reported positive updated results from a Phase 1/2 study of its gene therapy DB-OTO in the treatment of profound genetic hearing loss in children due to certain variants of the OTOF gene.